Literature DB >> 19786301

Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature.

Vincent Edgar Reyes, Tahseen Al-Saleem, Valentin G Robu, Mitchell R Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786301      PMCID： PMC2813903          DOI： 10.1016/j.leukres.2009.09.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  31 in total

Review 1.  Natural killer-cell malignancies: diagnosis and treatment.

Authors:  Y-L Kwong
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 2.  Development of human T and natural killer cells.

Authors:  H Spits; L L Lanier; J H Phillips
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

3.  Classification of natural killer (NK) cell and NK-like T-cell malignancies.

Authors:  E S Jaffe
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

4.  Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.

Authors:  M M Cheung; J K Chan; W H Lau; W Foo; P T Chan; C S Ng; R K Ngan
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma.

Authors:  Ye-Xiong Li; Bo Yao; Jing Jin; Wei-Hu Wang; Yue-Ping Liu; Yong-Wen Song; Shu-Lian Wang; Xin-Fan Liu; Li-Qiang Zhou; Xiao-Hui He; Ning Lu; Zi-Hao Yu
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

6.  L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.

Authors:  Weiben Yong; Wen Zheng; Jun Zhu; Yuntao Zhang; Xiaopei Wang; Yan Xie; Ningjing Lin; Bo Xu; Aiping Lu; Jiyou Li
Journal:  Ann Hematol       Date:  2008-12-24       Impact factor: 3.673

7.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.

Authors:  F Cabanillas; F B Hagemeister; G P Bodey; E J Freireich
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

8.  Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.

Authors:  M Yamaguchi; K Kita; H Miwa; K Nishii; K Oka; T Ohno; S Shirakawa; M Fukumoto
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

9.  Treatment outcome and prognostic factors for primary nasal lymphoma.

Authors:  R Liang; D Todd; T K Chan; E Chiu; A Lie; Y L Kwong; D Choy; F C Ho
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis.

Authors:  J A Ferry; J Sklar; L R Zukerberg; N L Harris
Journal:  Am J Surg Pathol       Date:  1991-03       Impact factor: 6.394
View more
  7 in total

1.  Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Authors:  Li Yang; Hong Liu; Xiao-hong Xu; Xin-feng Wang; Hong-ming Huang; Wen-yu Shi; Sheng-hua Jiang
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

2.  Primary extranodal NK/T-cell lymphoma of the lung: Mimicking bronchogenic carcinoma.

Authors:  Chia-Hsin Liu; Hong-Hau Wang; Cherng-Lih Perng; Chung-Kan Peng; Chih-Feng Chian; Chih-Hao Shen
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

Review 3.  Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets.

Authors:  Christian Schmitt; Nouhoum Sako; Martine Bagot; Yenlin Huang; Philippe Gaulard; Armand Bensussan
Journal:  J Biomed Biotechnol       Date:  2011-04-20

4.  Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.

Authors:  Lei Zhang; Sisi Jia; Yangyang Ma; Ling Li; Xin Li; Xinhua Wang; Xiaorui Fu; Wang Ma; Yanru Qin; Wencai Li; Jingjing Wu; Zhenchang Sun; Xudong Zhang; Feifei Nan; Yu Chang; Zhaoming Li; Dandan Zhang; Guannan Wang; Jiaqin Yan; Liping Su; Jinghua Wang; Hongwei Xue; Ken H Young; Mingzhi Zhang
Journal:  Oncotarget       Date:  2016-08-23

5.  Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.

Authors:  Jing-Hua Wang; Liang Wang; Cheng-Cheng Liu; Zhong-Jun Xia; Hui-Qiang Huang; Tong-Yu Lin; Wen-Qi Jiang; Yue Lu
Journal:  Oncotarget       Date:  2016-05-17

6.  Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.

Authors:  Jing-Hua Wang; Hua Wang; Yan-Jun Wang; Zhong-Jun Xia; Hui-Qiang Huang; Wen-Qi Jiang; Yue Lu
Journal:  Oncotarget       Date:  2016-06-07

Review 7.  Primary pulmonary extranodal NK/T-cell lymphoma of nasal type misdiagnosed as pneumonia: A case report and literature review.

Authors:  Juan Zhang; MaoJuan Wang; XiaoDong Yang; Chang Liu; Xin He
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.